Simplex Trading adds Intrexon Corp (XON) to its portfolio

Intrexon Corp (XON) : Simplex Trading added new position in Intrexon Corp during the most recent quarter end. The investment management firm now holds 12,904 shares of Intrexon Corp which is valued at $383,120 , the company said in a statement filed on Oct 7, 2016 with the SEC.Intrexon Corp makes up approximately 0.05% of Simplex Trading’s portfolio.

Other Hedge Funds, Including , Advisory Services Network boosted its stake in XON in the latest quarter, The investment management firm added 1,070 additional shares and now holds a total of 4,193 shares of Intrexon Corp which is valued at $124,490. Intrexon Corp makes up approx 0.02% of Advisory Services Network’s portfolio.Bnp Paribas Arbitrage Sa boosted its stake in XON in the latest quarter, The investment management firm added 570 additional shares and now holds a total of 1,820 shares of Intrexon Corp which is valued at $52,616. Washington Trust Bank sold out all of its stake in XON during the most recent quarter. The investment firm sold 2,000 shares of XON which is valued $57,820.

Intrexon Corp opened for trading at $28.47 and hit $29.75 on the upside on Friday, eventually ending the session at $29.69, with a gain of 4.07% or 1.16 points. The heightened volatility saw the trading volume jump to 13,87,993 shares. Company has a market cap of $3,513 M.

On the company’s financial health, Intrexon Corp reported $-0.42 EPS for the quarter, missing the analyst consensus estimate by $ -0.14 based on the information available during the earnings call on Aug 9, 2016. Analyst had a consensus of $-0.28. The company had revenue of $52.50 million for the quarter, compared to analysts expectations of $53.78 million. The company’s revenue was up 17.0% compared to the same quarter last year. During the same quarter in the previous year, the company posted $-0.37 EPS.

Intrexon Corporation is engaged in the field of synthetic biology. The Company designs builds and regulates gene programs which are Deoxyribonucleic Acid (DNA) sequences that consist of genetic components. The Company’s synthetic biology capabilities include the ability to control the amount location and modification of biological molecules to control the function and output of living cells. The Company’s technologies include UltraVector RheoSwitch Therapeutic System Cell Systems Informatics Protein Engineering AttSite Recombinases LEAP (Laser Enabled Analysis and Processing) Antibody Discovery Neurospora & Agaricus Platforms Endometrial Regenerative Cells ActoBiotics Porcine Research Models and BeyondBio. The Company serves various markets including health food energy environment and consumer. The Company has five operating divisions: Human Therapeutics Synthetic Immunology Animal Sciences Agricultural Biotech and Industrial Products.

Leave a Reply

Intrexon Corp - Is it time to Sell?

Top Brokerage Firms are advising their investors on Intrexon Corp. Subscribe to MoneyFlowIndex.Org Pre-Market Alerts, You will be the first to know the street buzz.